SCHEMBL5062003

SCHEMBL5062003

CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccnc(-c4cn[nH]c4)c3)cc2)n(-c2ccc3ncccc3c2)n1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 5/20 0.76
AXL P30530 2/20 0.76
SRC P12931 3/20 0.73
BRAF P15056 11/20 0.58
MAPK14 Q16539 3/20 0.58
EPHB4 P54760 2/20 0.58
MAPK11 Q15759 2/20 0.58
PTK2 Q05397 2/20 0.58
PTK2B Q14289 2/20 0.58
FLT3 P36888 2/20 0.58
PLK4 O00444 1/20 0.58
ACOX3 O15254 1/20 0.58
MAP3K7 O43318 1/20 0.58
DYRK3 O43781 1/20 0.58
JAK2 O60674 1/20 0.58
ERN1 O75460 1/20 0.58
RPS6KA4 O75676 1/20 0.58
STK10 O94804 1/20 0.58
MAP4K4 O95819 1/20 0.58
RAF1 P04049 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5055170 0.91 ABL1 (0.72) ABL1AXLSRCBRAFMAPK14
SCHEMBL5052351 0.90 BRAF (0.73) ABL1AXLSRCBRAFMAPK14
SCHEMBL5060252 0.89 ABL1 (0.59) ABL1AXLSRCBRAFMAPK14
SCHEMBL5062447 0.89 MAPK13 (0.59) ABL1AXLSRCBRAFMAPK14
SCHEMBL5060009 0.89 ABL1 (0.58) ABL1AXLSRCBRAFMAPK14
SCHEMBL5060665 0.88 ABL1 (0.75) ABL1AXLSRCBRAFMAPK14
SCHEMBL19911121 0.87 ABL1 (1.00) ABL1AXLSRCBRAFMAPK14
SCHEMBL5062147 0.87 BRAF (0.62) ABL1AXLSRCBRAFMAPK14
SCHEMBL5062338 0.87 ABL1 (0.56) ABL1AXLSRCBRAFMAPK14
SCHEMBL5052992 0.86 ABL1 (0.56) ABL1AXLSRCBRAFMAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080113967-A1 ENZYME MODULATORS AND TREATMENTS DECIPHERA PHARMACEUTICALS, LLC (US) 2008-05-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113967-A1 ENZYME MODULATORS AND TREATMENTS ABL2, BRAF, MAP3K1 ABL1 20/4885AXL 117/4885SRC 69/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.